日期： 2026 年 9 月 21 日, 星期一
时间： 9:00 AM – 4:30 PM
地点： Cambridge Innovation Center (CIC), 1 Broadway, 5th Floor, Havana Room | Cambridge, MA
议程
What it takes to walk into RESI & JPM with a program that holds up to investor scrutiny, from science to story.
Learn what investors really look for in a pitch: a well-defined medical need, genuine differentiation, and the regulatory and commercial foresight to back it up.
Get a clear-eyed view of today’s regulatory landscape and how to build a realistic path from IND to first-in-human that also satisfies investors and partners.
Understand what “investor-ready” evidence looks like, from translational relevance to study design to manufacturability and how it translates into value-driving milestones.
Secure your spot for one-on-one sessions with Certara experts and connect with peers over lunch.
Moderated panel featuring LSN’s perspective, as organizers of RESI on the factor’s investors weigh beyond the science.
A forward-looking conversation on how recent regulatory shifts are changing the way companies need to think and plan earlier in development, with a look at where the real opportunities are right now.
The practical, tactical piece – how to prepare before the conference, run productive meetings during it, and convert conversations into real momentum after it ends.
Hear from biotech leaders, investors, pharma, and Certara experts on how early strategic decisions shape risk, speed, and fundability.
Recap key insights and learn how to continue the conversation with Certara’s experts.
Join interactive breakout tables with Certara and LSN experts covering every theme from the day – from regulatory strategy to RESI/JPM prep – to explore solutions for your specific challenges
President & Chief Operating Officer
Life Science Nation
Sougato leads the RESI Conferences and the Investor and Licensing Partner Database at LSN, driving the company’s expansion from early-stage funding into a full seed-to-exit partnering platform. He brings deep experience across partnering conferences, data platforms, and biopharma, previously General Manager of the events and data business at Inpart, following two successful exits from biopharma data startups. He has held senior partnering and marketing roles at BIO and Clarivate, and has consulted for J&J, Merck, GSK, Sanofi, and Siemens Medical.
CEO & Founder, SynaptImmune Therapeutics
Tony is CEO /Founder Synaptimmune Therapeutics, Developing the next generation “Conditionally active and Costimulatory T cell engagers (TCE)” for Autoimmune and Solid tumor indications. He is also the Co-Founder of NextPoint therapeutics, an MPM capital-funded novel IO checkpoint inhibitor, TCE and ADC clinical stage company. Previously Senior Vice President and Head of R&D at Cytovia Therapeutics and held senior management positions at PTC, Alexion, Regeneron, Biogen, Dyax and Ares-Serono developing immunotherapys for autoimmunity and cancer. He is an immunologist with 20+ years of research and development experience developing multiple immunotherapies for autoimmune/inflammatory diseases and cancer including 3 BLAs (TysabriTM, KevzaraTM, DupixentTM ) and multiple INDs.
Vice President, Head of DMPK and Toxicology, Pioneering Medicines
Wojciech Dworakowski joined Flagship Pioneering in 2022 as Vice President, Head of DMPK and Toxicology for Pioneering Medicines. Wojciech and his team drive the evaluation of drug metabolism, safety, and pharmacokinetic/pharmacodynamic properties of therapeutic agents developed by the portfolio of Pioneering Medicines programs.
CEO, Akttyva Therapeutics
Dr. Katya Tsaioun is a translational scientist and biotechnology entrepreneur specializing in preclinical research, early safety assessment, and drug development. Through her consulting practice she serves as a fractional Chief Scientific Officer, board member, and advisor to biotechnology companies and venture capital firms, focusing on scientific due diligence, development strategy, and risk mitigation in drug-development programs. She founded Apredica, a pioneer in in vitro ADME and toxicology technologies acquired by Cyprotex PLC, where she became Chief Scientific Officer, and later co-founded Akttyva Therapeutics. From 2015 to 2025 she led the Evidence-Based Toxicology Collaboration at the Johns Hopkins Bloomberg School of Public Health.
Founder & President, Parasail LLC
Dustin is the Founder and President of Parasail LLC. A serial entrepreneur, Dr. Armstrong has founded more than 4 companies and raised over $60M amongst corporate venture groups, traditional VCs, and family-offices. As owner of Parasail, he has expanded clinical development of VAL-1221, an antibody-enzyme fusion, across a basket of polyglucosan disorders; including, Lafora disease the most severe form of genetic epilepsy and childhood dementia. Parasail’s pipeline also includes a best-in-class oligonucleotide-delivery platform, a stealth nutraceutical and a clinic-ready antibody immunotherapy (DemandFc; hu3E10 IgG1). DemandFc is the first and only anti-DNA antibody designed to neutralize circulating cell free DNA (cfDNA) in patients with autoimmune pathology. Dustin invented DemandFc following a personal family illness and Parasail is now preparing for First-In-Human (FIH) clinical testing in 2027.
Partner, Mid Atlantic Bio Angels & EisnerAmper
John Pennett is the Partner-in-Charge of EisnerAmper’s Life Sciences Group and Technology Group. He has 30 years of public accounting experience, with a strong emphasis on public and private life science and technology companies.
Principal, Fast Track Initiative
Dr. Koji Yasuda is Principal of Fast Track Initiative and has a unique background encompassing VC-backed biotech startups and global pharmaceutical companies. Notably, Dr. Yasuda was among the founding members of Kintai Therapeutics (now Senda Biosciences), a NewCo originating from Flagship Pioneering, the Venture Capital firm behind Moderna. Dr. Yasuda’s seminal PhD research at Harvard formed the basis for Kintai’s original IPs. His instrumental contributions played a key role in securing substantial funding rounds for Kintai, including $50M Series A, followed by $98M Series B and most recently, $123M Series C funding round.
Fran Brown, PhD
Senior Vice President, Global Head, Drug Development Science从药物早期发现到报批和上市后，Fran 在全球战略性和运营性药物开发方面拥有超过 25 年的经验。她在战略性药物发现和开发方面拥有广泛的知识，尤其侧重于发展策略和模型引导的药物开发 (MIDD) 的应用。
Maximilian Vargas, PhD, MBA
Vice President, Evidence & Access StrategyMax brings both scientific training and experience in healthcare product development that are important for evidence-based value and access strategies for pipeline and marketed products. Leading a team of analysts and focusing on projects involving late stage, launch, and due diligence efforts, Max’ experience cuts across all major therapeutic areas and care settings with special emphasis on CV / metabolic, oncology, gene therapies, ophthalmology, GI, and dermatology. Max and team have designed successful pricing and contracting strategies for products at launch and throughout the life cycle. He also leads projects focusing on managed markets communications strategies.
Colin Callaghan, RPh, MBA
Senior Director, Program LeadershipColin has 33 years in the pharmaceutical industry primarily in multi-disciplinary drug development leadership roles, including 25 years with early development/early-stage programs.
At Certara, Colin leads numerous programs in Oncology, CNS, Infectious Disease and Global Health therapeutic areas and supports biotech companies with their funding initiatives. Prior to Certara, Colin worked for very large (Pfizer, Wyeth-Ayerst), mid-size (Celldex), and start-up (Kolltan, Iterum, Maxwell BioSciences) pharmaceutical companies as well as consultant firms (Deloitte and Lachman Consultants) in drug development, business operations and process improvement roles. He earned an undergraduate degree in Pharmacy from Rutgers University and an MBA degree from the University of North Carolina – Wilmington.
Kevin Hershberger, BPharm, MBA
Vice President Nonclinical Development Sciences, CertaraKevin 在制药行业拥有 25 年的从业经验，主要从事项目领导工作，提供综合项目管理服务，包括统筹计划、目标产品特征（TPP）、客户财务规划，涉及融资、业务拓展、客户提案及供应商筛选。He has held leadership and management roles at Brighton Biotech, deCODE Genetics, Parke-Davis, Pfizer and Takeda.
Geoff Fatzinger
Vice President, Regulatory Strategy, CertaraGeoff 拥有 20 多年的专业经验，在美国、欧洲、亚太地区（在日本、中国和韩国有深入的经验）和中东地区的监管和业务成就有目共睹。
Tong Zhu, PhD, FCP
VP, Global Head, Clinical Pharmacology & Translational Medicine Certara Drug Development SolutionsDr. Tong Zhu 拥有超过 25 年专注于转化医学、早期开发及临床药理学的丰富经验，对药物研发领域有着深厚的专业知识。对药物研发领域有着深厚的专业知识。她曾负责领导 Astellas 线粒体生物学重点战略，通过全球合作，帮助识别和开发针对线粒体生物学的创新药物。在 Astellas 近 14 年的职业生涯中，她曾在临床药理学与探索性开发部门担任过多个领导职务。加入 Astellas 之前，Dr. Zhu 在雅培全球药物研发部门（现为 AbbVie）的临床药理学和药物代谢动力学团队中担任了重要职位。
Diana Marcantonio, PhD
Senior Director, QSPDiana Marcantonio has 20+ years of experience, including 15+ years in pharmaceutical and biotech industries, with a background in biological engineering. In her current role, she is responsible for guiding strategy and providing biological and disease area expertise on modeling projects to help clients make informed decisions during drug R&D. Prior to joining Certara, she worked in drug discovery research, where she led cross-disciplinary project teams from target identification through lead selection.
精选推荐
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
